Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    optinose
Show Display Options
RSS Create an RSS feed from your search for:
optinose
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
Condition: Migraine
Intervention: Drug: Sumatriptan
2 Completed A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
Condition: Mild to Moderate Asthma
Interventions: Drug: Flovent HFA;   Drug: OPTINOSE™ FLUTICASONE
3 Completed Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder
Condition: Autism Spectrum Disorder
Interventions: Drug: 8IU intranasal oxytocin;   Drug: 24IU intranasal oxytocin;   Drug: Placebo;   Device: OptiNose Breath Powered Bi
4 Completed Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without
Conditions: Migraine;   Headaches
Interventions: Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally;   Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
5 Completed Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Condition: Healthy Male Adults
Interventions: Drug: 8IU intranasal oxytocin;   Drug: 24 IU intranasal oxytocin;   Drug: 1 IU intravenous oxytocin;   Drug: Placebo
6 Completed
Has Results
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
Condition: Migraine Headache
Interventions: Drug: Sumatriptan;   Drug: Placebo
7 Completed Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate
Condition: Bilateral Nasal Polyposis
Intervention: Drug: Rescue Med
8 Completed
Has Results
Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
Condition: Chronic Sinusitis With or Without Nasal Polyps
Intervention: Drug: Fluticasone Propionate
9 Completed 12-Month OL Safety Study of Intranasal 400 μg of Fluticasone Propionate BID Using a Novel Bi-Directional Device in CS Patients
Condition: Chronic Sinusitis: [Nos] or [Ethmoidal] or [Chronic Pansinusitis] or [Sphenoidal]
Intervention: Drug: rescue med
10 Completed Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Condition: Bilateral Nasal Polyposis
Intervention: Drug: rescue med

Indicates status has not been verified in more than two years